FibroGen Statistics

Total Valuation

FibroGen has a market cap or net worth of MXN 436.75 million. The enterprise value is 2.32 billion.

Market Cap	436.75M
Enterprise Value	2.32B

Important Dates

The next estimated earnings date is Monday, August 4, 2025.

Earnings Date	Aug 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	4.04M
Shares Outstanding	n/a
Shares Change (YoY)	+2.20%
Shares Change (QoQ)	+0.12%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	3.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.05
PB Ratio	-0.12
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-11.35
EV / Sales	17.53
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.49

Financial Position

The company has a current ratio of 2.02

Current Ratio	2.02
Quick Ratio	0.46
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-1.20
Interest Coverage	-11.48

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-22.73%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-105.17%
Revenue Per Employee	635,514
Profits Per Employee	-909,031
Employee Count	225
Asset Turnover	0.03
Inventory Turnover	4.12

Taxes

Income Tax	-5.60M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -79.15% in the last 52 weeks. The beta is 0.82, so FibroGen's price volatility has been lower than the market average.

Beta (5Y)	0.82
52-Week Price Change	-79.15%
50-Day Moving Average	148.53
200-Day Moving Average	197.49
Relative Strength Index (RSI)	25.98
Average Volume (20 Days)	7

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.89

Income Statement

In the last 12 months, FibroGen had revenue of MXN 142.99 million and -204.53 million in losses. Loss per share was -50.86.

Revenue	142.99M
Gross Profit	-1.14B
Operating Income	-1.97B
Pretax Income	-2.47B
Net Income	-204.53M
EBITDA	-1.93B
EBIT	-1.97B
Loss Per Share	-50.86

Full Income Statement

Balance Sheet

The company has 686.93 million in cash and 1.86 billion in debt, giving a net cash position of -1.18 billion.

Cash & Cash Equivalents	686.93M
Total Debt	1.86B
Net Cash	-1.18B
Net Cash Per Share	n/a
Equity (Book Value)	-3.58B
Book Value Per Share	-1,096.83
Working Capital	1.54B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.55 billion and capital expenditures -5.17 million, giving a free cash flow of -1.56 billion.

Operating Cash Flow	-1.55B
Capital Expenditures	-5.17M
Free Cash Flow	-1.56B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,380.42%
Pretax Margin	-1,730.87%
Profit Margin	-143.04%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FibroGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.20%
Shareholder Yield	n/a
Earnings Yield	-46.83%
FCF Yield	-356.81%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 17, 2025. It was a reverse split with a ratio of 0.04.

Last Split Date	Jun 17, 2025
Split Type	Reverse
Split Ratio	0.04

Scores

FibroGen has an Altman Z-Score of -17.19 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-17.19
Piotroski F-Score	1